27262143|t|Novel immunotherapeutic strategies to target alloantibody -producing B and plasma cells in transplantation
27262143|a|There is an unmet need for immunotherapeutic agents that target humoral alloimmunity in solid organ transplantation. This includes sensitized patients with preformed donor -specific human leucocyte antigen antibodies and patients who develop de-novo donor -specific antibodies, both of which are associated with acute and chronic antibody-mediated rejection and allograft loss. In this review, we discuss recent progress in the generation of B-cell and plasma cell -targeted therapeutics, with an emphasis on novel agents. To deplete or inhibit B cells, B-cell -specific mAbs have been developed, including CD20, CD22, CD19 and bi-specific antibodies that target two B-cell antigens. In addition, inhibition of B-cell - activating cytokines, such as B cell-activating factor, may also reduce allo-B-cell activation. Plasma cells remain a difficult therapeutic target, but inhibition of germinal centre responses via costimulatory blockade or IL21 neutralization, induction of plasma cell apoptosis using proteasome inhibitors or disruption of the plasma cell niche are potential avenues being explored. The ultimate aim of these animal and human studies is to develop agents that efficiently target humoral effectors, whilst sparing B and plasma cells with a regulatory capacity to promote long-term allograft survival, but we remain some distance away from this goal.
27262143	0	5	Novel	T080	C0205314
27262143	6	34	immunotherapeutic strategies	T061	C0021083
27262143	38	44	target	T169	C1521840
27262143	45	57	alloantibody	T129	C0022144
27262143	69	70	B	T025	C0004561
27262143	75	87	plasma cells	T025	C0032112
27262143	91	106	transplantation	T061	C0040732
27262143	134	158	immunotherapeutic agents	T121,T129	C0876248
27262143	164	170	target	T169	C1521840
27262143	171	191	humoral alloimmunity	T042	C0598604
27262143	195	222	solid organ transplantation	T061	C0029216
27262143	238	257	sensitized patients	T101	C0030705
27262143	273	278	donor	T098	C0029206
27262143	289	312	human leucocyte antigen	T116,T129	C0019721
27262143	313	323	antibodies	T116,T129	C0003241
27262143	328	336	patients	T101	C0030705
27262143	349	356	de-novo	T078	C1515568
27262143	357	362	donor	T098	C0029206
27262143	373	383	antibodies	T116,T129	C0003241
27262143	403	418	associated with	T080	C0332281
27262143	419	424	acute	T079	C0205178
27262143	429	436	chronic	T079	C0205191
27262143	437	464	antibody-mediated rejection	T046	C1608421
27262143	469	478	allograft	T061	C0040739
27262143	479	483	loss	T081	C1517945
27262143	493	499	review	T170	C0282443
27262143	519	527	progress	T169	C1280477
27262143	535	545	generation	T052	C3146294
27262143	549	555	B-cell	T025	C0004561
27262143	560	571	plasma cell	T025	C0032112
27262143	582	594	therapeutics	T061	C0087111
27262143	616	621	novel	T080	C0205314
27262143	622	628	agents	T120	C0450442
27262143	633	640	deplete	T169	C0333668
27262143	644	651	inhibit	T052	C3463820
27262143	652	659	B cells	T025	C0004561
27262143	661	667	B-cell	T025	C0004561
27262143	678	682	mAbs	T116,T129	C0003250
27262143	714	718	CD20	T116,T129	C0054946
27262143	720	724	CD22	T116,T129	C0054947
27262143	726	730	CD19	T116,T129	C0108748
27262143	747	757	antibodies	T116,T129	C0003241
27262143	763	769	target	T169	C1521840
27262143	774	780	B-cell	T025	C0004561
27262143	781	789	antigens	T129	C0003320
27262143	804	814	inhibition	T052	C3463820
27262143	818	824	B-cell	T025	C0004561
27262143	827	837	activating	T043	C1326120
27262143	838	847	cytokines	T116,T129	C0079189
27262143	857	881	B cell-activating factor	T116,T123	C1682317
27262143	899	921	allo-B-cell activation	T043	C2259068
27262143	923	935	Plasma cells	T025	C0032112
27262143	955	966	therapeutic	T061	C0087111
27262143	967	973	target	T169	C1521840
27262143	979	989	inhibition	T052	C3463820
27262143	993	1008	germinal centre	T024	C0282491
27262143	1009	1018	responses	T032	C0871261
27262143	1037	1045	blockade	T169	C0332206
27262143	1049	1053	IL21	T116,T129	C0962190
27262143	1054	1068	neutralization	T169	C2987668
27262143	1070	1079	induction	T169	C0205263
27262143	1083	1094	plasma cell	T025	C0032112
27262143	1095	1104	apoptosis	T043	C0162638
27262143	1111	1132	proteasome inhibitors	T121	C1443643
27262143	1136	1146	disruption	T169	C0332453
27262143	1154	1165	plasma cell	T025	C0032112
27262143	1223	1226	aim	T078	C1947946
27262143	1236	1242	animal	T008	C0003062
27262143	1247	1260	human studies	T062	C0178693
27262143	1299	1305	target	T169	C1521840
27262143	1306	1323	humoral effectors	T025	C0312740
27262143	1340	1341	B	T025	C0004561
27262143	1346	1358	plasma cells	T025	C0032112
27262143	1366	1376	regulatory	T077	C1704735
27262143	1377	1385	capacity	T033	C0518031
27262143	1407	1416	allograft	T061	C0040739
27262143	1417	1425	survival	T042	C0018131
27262143	1470	1474	goal	T170	C0018017